Adaptimmune Ltd.
57c Milton Park
Abingdon
Oxfordshire
OX14 4RX
United Kingdom
Tel: +44-(0)-1235-438-642
Fax: +44-(0)-1235-438-607
Website: http://www.adaptimmune.com/
131 articles about Adaptimmune Ltd.
-
Adaptimmune’s NY-ESO-1 TCR-Engineered T-Cells Demonstrate Durable Persistence, Clinical Activity And Tolerability In Clinical Study In Multiple Myeloma Patients
7/20/2015
-
Adaptimmune Announces FDA Acceptance Of Investigational New Drug (IND) Application For MAGE-A10 T In Patients With Non-Small Cell Lung Cancer
7/2/2015
-
ASCO15: Adaptimmune Announces Data From Clinical Studies Of NY-ESO-1 Specific T-Cells In Multiple Cancers At The 2015 Annual ASCO Meeting
6/1/2015
-
Adaptimmune Announces New Additions To Senior Clinical Management
5/20/2015
-
Citi Appointed Depositary Bank For Adaptimmune’s ADR Programme
5/19/2015
-
Adaptimmune Announces Upcoming Data Presentation At The 2015 Annual American Society Of Gene And Cell Therapy (ASGCT) Meeting
5/13/2015
-
Adaptimmune Announces Appointment Of Vice President Of Investor Relations
5/13/2015
-
Adaptimmune Announces Closing Of IPO
5/11/2015
-
Adaptimmune Announces Pricing Of IPO
5/6/2015
-
Fidelity CEO Uses Personal Fortune to Bet on Cancer Related IPOs Like Coherus, Adaptimmune and Blueprint Medicines
4/13/2015
-
Adaptimmune Ltd. Appoints Lawrence M. Alleva To Its Board Of Directors
3/10/2015
-
Adaptimmune Ltd. Strengthens Management Team With Key Executive Hires
3/4/2015
-
Adaptimmune Ltd. Announces Interim Results From Pilot Trial Of Its Engineered NY-ESO T Cells Targeting Synovial Sarcoma
10/17/2014
-
UK Biotech Firm Adaptimmune Ltd. Attracts $104 Million Investment
9/25/2014
-
Adaptimmune Ltd. Gets Ready To Double Headcount By The End Of 2014
6/5/2014
-
Adaptimmune Ltd., GlaxoSmithKline Strike $350 Million Cancer Immunotherapy Pact
6/2/2014
-
Adaptimmune Ltd. Integrates BioLife Solutions, Inc. CryoStor® Cell Freeze Media In Cancer Immunotherapy Clinical Trial
4/2/2014
-
Adaptimmune Ltd. Announces Full-Time Appointment Of James Noble As Chief Executive Officer
3/26/2014
-
Adaptimmune Ltd. Announces Award Of £2.1 Million From The Biomedical Catalyst Fund
3/25/2014
-
Adaptimmune Ltd. Announces Interim Results From A Phase I/II Trial Of Engineered T Cells Targeting Cancer Testis Antigens In Multiple Myeloma
12/10/2013